Workflow
iHuman English
icon
Search documents
iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results
Prnewswire· 2025-12-29 09:11
Core Insights - iHuman Inc. reported its unaudited financial results for Q3 2025, highlighting a strategic focus on product innovation and expansion into older age cohorts to enhance user engagement and long-term growth [1][4][9]. Financial Performance - Revenues for Q3 2025 were RMB205.8 million (US$28.9 million), a decrease from RMB239.4 million in the same period last year, attributed to a decline in China's newborn population and conservative consumer spending [7][10]. - Gross profit was RMB140.6 million (US$19.8 million), down from RMB163.9 million year-over-year, with a gross margin of 68.3% compared to 68.4% in the previous year [12]. - Operating income decreased to RMB16.7 million (US$2.3 million) from RMB20.7 million in the same period last year [15]. - Net income was RMB21.6 million (US$3.0 million), down from RMB25.1 million year-over-year, with basic and diluted net income per ADS at RMB0.42 (US$0.06) and RMB0.40 (US$0.06), respectively [16]. User Engagement and Market Reach - Average total Monthly Active Users (MAUs) for Q3 were 26.13 million, down from 29.12 million in the same period last year, primarily due to the decline in China's newborn population [10]. - The company launched the second season of its successful Kunpeng Animation Studio's "Rainbow Crew," which has maintained high rankings among children's programs on major streaming platforms, enhancing brand influence [8]. Product Innovation - iHuman has made significant advancements in its product offerings, including enhancements to the iHuman English app and the introduction of the iHuman AI Pal, a plush AI companion designed to support children's learning and emotional development [5][6]. - The company is expanding its digital products into smart home ecosystems and in-vehicle experiences, partnering with NIO to integrate core apps into their electric vehicles, thereby broadening user access [9]. Financial Health - Cash, cash equivalents, and short-term investments totaled RMB1,128.2 million (US$158.5 million) as of September 30, 2025, a slight decrease from RMB1,168.7 million at the end of 2024 [18]. - Deferred revenue and customer advances were RMB230.4 million (US$32.4 million) as of September 30, 2025, down from RMB283.3 million at the end of 2024 [17]. Strategic Outlook - The company plans to continue prioritizing strategic investments in innovation and technology to meet evolving family needs, maintaining confidence in its brand and product pipeline for future growth [9].